Skip to main content

Gracell Biotechnologies, Inc. (GRCL)

NASDAQ: GRCL · IEX Real-Time Price · USD
13.60 0.81 (6.33%)
Sep 24, 2021 4:00 PM EDT - Market closed
Market Cap914.51M
Revenue (ttm)n/a
Net Income (ttm)n/a
Shares Out67.24M
EPS (ttm)-1.34
PE Ration/a
Forward PEn/a
Dividendn/a
Ex-Dividend Daten/a
Volume46,368
Open12.60
Previous Close12.79
Day's Range12.56 - 14.04
52-Week Range9.75 - 33.70
Betan/a
AnalystsStrong Buy
Price Target34.67 (+154.9%)
Est. Earnings DateNov 16, 2021

About GRCL

Gracell Biotechnologies Inc., a clinical-stage biopharmaceutical company, primarily discovers and develops cell therapies for the treatment of cancer in the People's Republic of China. Its lead product candidates include GC012F, a FasTCAR-enabled dual BCMA- and CD19-directed autologous CAR-T product candidate that is in Phase I trial for the treatment of multiple myeloma; GC019F, a FasTCAR-enabled CD19-directed autologous CAR-T product candidate, which is in Phase I clinical trial for the treatment of adult B cell acute lymphoblastic leukemia (...

IndustryBiotechnology
IPO DateJan 8, 2021
Employees202
Stock ExchangeNASDAQ
Ticker SymbolGRCL
Full Company Profile

Financial Performance

Financial numbers in millions CNYFinancial Statements

Analyst Forecast

According to 3 analysts, the average rating for GRCL stock is "Strong Buy." The 12-month stock price forecast is 34.67, which is an increase of 154.93% from the latest price.

Price Target
$34.67
(154.93% upside)
Analyst Consensus: Strong Buy

News

Gracell Biotechnologies to Participate in Upcoming Virtual Investor Conferences in September

SUZHOU, China and PALO ALTO, Calif., Aug. 26, 2021 (GLOBE NEWSWIRE) -- Gracell Biotechnologies Inc. (NASDAQ: GRCL) (“Gracell”), a global clinical-stage biopharmaceutical company dedicated to discovering...

1 month ago - GlobeNewsWire

Gracell Biotechnologies Reports Second Quarter 2021 Unaudited Financial Results and Provides Corporate Update

SUZHOU, China and PALO ALTO, Calif., Aug. 17, 2021 (GLOBE NEWSWIRE) -- Gracell Biotechnologies Inc. (NASDAQ: GRCL) (“Gracell”), a global clinical-stage biopharmaceutical company dedicated to discovering...

1 month ago - GlobeNewsWire

Gracell Biotechnologies Signs Exclusive License Agreement with FutureGen Biopharm to Develop Engineered Immune Cell T...

SUZHOU and SHANGHAI, China, and PALO ALTO, Calif., Aug. 16, 2021 /PRNewswire/ -- Gracell Biotechnologies Inc. (NASDAQ: GRCL) ("Gracell"), a global clinical-stage biopharmaceutical company dedicated to d...

1 month ago - PRNewsWire

Gracell Biotechnologies to Participate in Fireside Chat at the BTIG Virtual Biotechnology Conference

SUZHOU, China and PALO ALTO, Calif., July 26, 2021 (GLOBE NEWSWIRE) -- Gracell Biotechnologies Inc. (NASDAQ: GRCL) (“Gracell”), a global clinical-stage biopharmaceutical company dedicated to discovering...

2 months ago - GlobeNewsWire

All You Need to Know About Gracell Biotechnologies Inc. Sponsored ADR (GRCL) Rating Upgrade to Buy

Gracell Biotechnologies Inc. Sponsored ADR (GRCL) might move higher on growing optimism about its earnings prospects, which is reflected by its upgrade to a Zacks Rank #2 (Buy).

2 months ago - Zacks Investment Research

Gracell Biotechnologies Reschedules Clinical Update Conference Call and Webcast to June 14, 2021

SUZHOU, China and PALO ALTO, Calif., June 02, 2021 (GLOBE NEWSWIRE) -- Gracell Biotechnologies Inc. (NASDAQ: GRCL) (“Gracell”), a global clinical-stage biopharmaceutical company dedicated to discovering...

3 months ago - GlobeNewsWire

Gracell Biotechnologies Hosting Key Opinion Leader Webinar on High Risk Multiple Myeloma, Treatment Challenges and Du...

SUZHOU, China and PALO ALTO, Calif., May 26, 2021 /PRNewswire/ -- Gracell Biotechnologies Inc. (NASDAQ: GRCL) ("Gracell"), a global clinical-stage biopharmaceutical company dedicated to discovering and ...

4 months ago - PRNewsWire

Gracell Biotechnologies to Participate in Upcoming Virtual Conferences in June

SUZHOU, China and PALO ALTO, Calif., May 25, 2021 (GLOBE NEWSWIRE) -- Gracell Biotechnologies Inc. (NASDAQ: GRCL) (“Gracell”), a global clinical-stage biopharmaceutical company dedicated to discovering ...

4 months ago - GlobeNewsWire

Gracell Biotechnologies to Host Clinical Update Conference Call and Webcast on June 4, 2021 at 11:00am EDT

SUZHOU, China and PALO ALTO, Calif., May 21, 2021 (GLOBE NEWSWIRE) -- Gracell Biotechnologies Inc. (NASDAQ: GRCL) (“Gracell”), a global clinical-stage biopharmaceutical company dedicated to discovering ...

4 months ago - GlobeNewsWire

Gracell Biotechnologies to Present Updated Results of GC012F FasTCAR-enabled BCMA/CD19 Dual-targeting CAR-T Cell Ther...

SUZHOU, China and PALO ALTO, Calif. , May 19, 2021 /PRNewswire/ --  Gracell Biotechnologies Inc. (NASDAQ: GRCL) ("Gracell"), a global clinical-stage biopharmaceutical company dedicated to developing hig...

4 months ago - PRNewsWire

Gracell Biotechnologies Reports First Quarter 2021 Unaudited Financial Results and Provides Corporate Update

Reported updated long-term follow-up data for TruUCAR-enabled CD7-targeted CAR-T product candidate GC027 for the treatment of T-ALL at AACR 2021 Annual Meeting

4 months ago - GlobeNewsWire

Gracell Biotechnologies Appoints Seasoned Gene & Cell Therapy Executive Dr. Jenny (Yajin) Ni as Chief Technology Officer

SUZHOU and SHANGHAI, China, May 10, 2021 /PRNewswire/ -- Gracell Biotechnologies Inc. (NASDAQ: GRCL) ("Gracell"), a global clinical-stage biopharmaceutical company dedicated to developing highly efficac...

4 months ago - PRNewsWire

Gracell Biotechnologies to Participate in Upcoming Virtual Conferences in May

SUZHOU and SHANGHAI, China, April 30, 2021 (GLOBE NEWSWIRE) -- Gracell Biotechnologies Inc. (NASDAQ: GRCL) (“Gracell”), a global clinical-stage biopharmaceutical company dedicated to discovering and dev...

4 months ago - GlobeNewsWire

Gracell Biotechnologies Announces Filing of Its Annual Report on Form 20-F for Fiscal Year 2020

SUZHOU and SHANGHAI, China, April 23, 2021 (GLOBE NEWSWIRE) -- Gracell Biotechnologies Inc. (NASDAQ: GRCL) (“Gracell”), a global clinical-stage biopharmaceutical company dedicated to developing highly e...

5 months ago - GlobeNewsWire

Gracell Biotechnologies Reports Long-term Follow-up Data on TruUCAR-enabled GC027 in Relapsed/Refractory T-ALL at the...

SUZHOU and SHANGHAI, China, April 10, 2021 /PRNewswire/ -- Gracell Biotechnologies Inc. (NASDAQ: GRCL) ("Gracell"), a global clinical-stage biopharmaceutical company dedicated to developing highly effic...

5 months ago - PRNewsWire

Gracell Biotechnologies to Present at the 20th Annual Needham Virtual Healthcare Conference

SUZHOU, China and SHANGHAI, China, April 05, 2021 (GLOBE NEWSWIRE) -- Gracell Biotechnologies Inc. (NASDAQ: GRCL) (“Gracell”), a global clinical-stage biopharmaceutical company dedicated to discovering ...

5 months ago - GlobeNewsWire

Gracell Biotechnologies Signs Agreement with Lonza to Manufacture Gracell's FasTCAR Product Candidates in the U.S.

SUZHOU, China and PALO ALTO, Calif., March 31, 2021 /PRNewswire/ -- Gracell Biotechnologies Inc. (NASDAQ:GRCL)("Gracell"), a global clinical-stage biopharmaceutical company dedicated to discovering and ...

5 months ago - PRNewsWire

Gracell Biotechnologies Announces Enrollment of First Patient in Registrational Phase 1/2 Clinical Study for GC007g, ...

SUZHOU and SHANGHAI, China, March 31, 2021 /PRNewswire/ -- Gracell Biotechnologies Inc. (NASDAQ: GRCL) ("Gracell"), a global clinical-stage biopharmaceutical company dedicated to developing highly effic...

5 months ago - PRNewsWire

Gracell Biotechnologies to Participate in the 2021 Virtual Wells Fargo Biotech Corporate Access Day

SUZHOU and SHANGHAI, China, March 17, 2021 (GLOBE NEWSWIRE) -- Gracell Biotechnologies Inc. (NASDAQ: GRCL) (“Gracell”), a global clinical-stage biopharmaceutical company dedicated to discovering and dev...

6 months ago - GlobeNewsWire

Gracell Biotechnologies Reports Fourth Quarter and Fiscal Year 2020 Unaudited Financial Results and Provides Corporat...

Reported interim readouts for lead CAR-T product candidates: FasTCAR-enabled dual-targeting BCMA/CD19 autologous CAR-T product candidate GC012F for the treatment of multiple myeloma and TruUCAR-enabled ...

6 months ago - GlobeNewsWire

Gracell Biotechnologies Receives IND Approval from China NMPA for GC019F, a FasTCAR-Enabled CAR-T Therapy for the Tre...

SUZHOU and SHANGHAI, China, Jan. 19, 2021 /PRNewswire/ -- Gracell Biotechnologies Inc. (NASDAQ: GRCL) ("Gracell"), a global clinical-stage biopharmaceutical company dedicated to developing highly effica...

8 months ago - PRNewsWire

Gracell Biotechnologies Receives Medical Products Manufacturing Certificate for CAR-T Cell Therapy Products

SUZHOU, China, Jan. 15, 2021 /PRNewswire/ -- Gracell Biotechnologies Inc. (NASDAQ: GRCL) ("Gracell"), a global clinical-stage biopharmaceutical company dedicated to developing highly efficacious and aff...

8 months ago - PRNewsWire

China NMPA Grants Approval for the Registrational Phase 1/2 Clinical Study for GC007g - an Allogeneic CAR-T Cell Ther...

SUZHOU and SHANGHAI, China, Jan. 13, 2021 /PRNewswire/ -- Gracell Biotechnologies Inc. (NASDAQ: GRCL) ("Gracell"), a global clinical-stage biopharmaceutical company dedicated to developing highly effica...

8 months ago - PRNewsWire

China's Gracell Biotechnologies Lists on Nasdaq

Jan.10 -- William Cao, founder and chief executive officer of Gracell Biotechnologies, discusses the Shanghai-based company's initial public offering in the U.S. and its growth strategy. Gracell is deve...

8 months ago - Bloomberg Markets and Finance

Week In Review: China Biopharma Starts 2021 With Over $1 Billion In Deals And IPOs

Gracell Biotech completed a $209 million NASDAQ IPO for its next-gen CAR-T treatments. Zai Lab acquired greater China rights to an argenx SE novel treatment for autoimmune indications in a deal worth up...

8 months ago - Seeking Alpha